Following a complete response letter and biologics license application resubmission, the FDA has approved remestemcel-L for ...

Petros Grivas, MD, PhD, discusses the key trials of bladder cancer using immunotherapy he highlighted during a Case-Based ...

The FDA issued a complete response letter for the BLA submission of subcutaneous amivantamab for EGFR-mutated NSCLC, citing ...

Ensartinib has received FDA approval for the first-line treatment of anaplastic lymphoma kinase (ALK)-positive locally ...

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...

With the Oncology Brothers, Uma Borate, MD, discusses how CPX-351 demonstrates superior efficacy over 7+3 chemotherapy in ...

Alexa Simon Meara, MD, discusses the importance of including a rheumatology approach to immunotherapy treatment for cancer.

Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel ...

Panelists discuss how recent therapeutic advances, including novel drug combinations and personalized treatment approaches, ...

With the Oncology Brothers, Uma Borate, MD, discusses how the combination of venetoclax with an IDH1 inhibitor and 7+3 ...

With the Oncology Brothers, Uma Borate, MD, discusses how ziftomenib is showing promising results as a targeted therapy for ...

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and ...